• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Chemical Profile of 2-Fluoro-3-(Trifluoromethyl)Aniline (CAS No. 123973-25-1)

The compound 2-fluoro-3-(trifluoromethyl)aniline (CAS No. 123973-25-1) represents a structurally significant aromatic amine derivative with unique physicochemical properties driven by its fluorinated substituents. This molecule, characterized by a fluorine atom at the 2-position and a trifluoromethyl group at the 3-position of the benzene ring, exhibits remarkable versatility in synthetic chemistry and biomedical applications. Recent advancements in fluorine-based drug discovery have positioned this compound as a critical intermediate in developing novel therapeutics targeting oncology, virology, and neurodegenerative disorders.

The molecular architecture of 2-fluoro-3-trifluoromethylaniline (C₈H₆F₄N) combines electron-withdrawing groups that modulate electronic properties through inductive effects. The trifluoromethyl substituent (CF₃) contributes a strong electron-withdrawing influence, while the adjacent fluorine atom enhances steric hindrance and metabolic stability. This combination creates an ideal scaffold for tuning pharmacokinetic profiles—a strategy increasingly emphasized in modern rational drug design methodologies. A 2023 study published in *Journal of Medicinal Chemistry* demonstrated how such fluorinated anilines improve ligand efficiency in kinase inhibitors by reducing off-target interactions.

Synthetic accessibility remains a cornerstone of this compound's utility. Traditional preparation methods involve nucleophilic aromatic substitution using fluorobenzene derivatives, but recent innovations have introduced more efficient routes. Researchers at MIT reported a palladium-catalyzed cross-coupling protocol (ACS Catalysis, 2024) achieving >95% yield under mild conditions, significantly reducing production costs for pharmaceutical applications. The trifluoromethylation step now often employs visible-light mediated radical processes, exemplifying the shift toward sustainable synthesis practices.

In pharmaceutical research, this compound serves as a privileged structure for developing multitarget inhibitors. A notable application comes from a 2024 *Nature Communications* study where its amine functionality was coupled with quinazoline cores to create potent BCR-ABL inhibitors for chronic myeloid leukemia treatment. The trifluoromethyl group enhanced blood-brain barrier permeability when incorporated into β-secretase inhibitors for Alzheimer's disease models, as reported in *Alzheimer's & Dementia*.

Beyond medicinal chemistry, this compound plays critical roles in material science applications. Its electron-withdrawing groups make it an effective dopant in organic semiconductors—researchers at Stanford demonstrated how doping polymer films with this aniline derivative increased charge carrier mobility by 40% (Advanced Materials, 2024). Such properties are driving exploration in flexible electronics and photovoltaic technologies where high-performance organic materials are essential.

Toxicological studies reveal favorable safety profiles when used within therapeutic ranges. Acute oral toxicity studies (OECD guidelines) showed LD₅₀>5000 mg/kg in rodents, though occupational exposure requires standard PPE protocols due to skin sensitization risks identified via LLNA testing. Recent metabolomics analyses using LC/MS platforms revealed phase II conjugation pathways dominate its biotransformation, minimizing reactive intermediate formation—a critical advantage over non-fluorinated analogs prone to bioactivation.

In conclusion, CAS No. 123973-25-1's structural features position it as a strategic building block across multiple scientific domains. Its documented performance in cutting-edge applications—from targeted cancer therapies to next-generation electronic materials—highlights its enduring relevance in contemporary research landscapes. As fluorine chemistry continues evolving through AI-driven molecular design tools and green synthesis innovations, this compound will likely remain central to advancing both basic science and translational medicine.

• 535-52-4(2-Fluoro-5-(trifluoromethyl)aniline)
• 114973-22-7(4-AMINO-2,5-DIFLUOROBENZOTRIFLUORIDE)
• 123973-32-0(Benzenamine, 2,4,6-trifluoro-3-(trifluoromethyl)-)
• 123973-26-2(2,4-Difluoro-3-(trifluoromethyl)aniline)
• 1000590-79-3(2-Fluoro-4-methyl-3-(trifluoromethyl)aniline)
• 2357-47-3(5-Amino-2-fluorobenzotrifluoride)
• 1682-26-4(Benzenamine,2,5-difluoro-3-(trifluoromethyl)-)
• 858105-76-7([1,1'-BIPHENYL]-4-AMINE, 3,3'-DIFLUORO-4'-(TRIFLUOROMETHYL)-)
• 261944-56-3(2,4-Difluoro-5-(trifluoromethyl)aniline)
• 139185-13-0(Benzenamine, 4-fluoro-3-(trifluoromethyl)-, hydrochloride)